Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Dermata Therapeutics Inc WT (DRMAW)

Dermata Therapeutics Inc WT (DRMAW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Dermata’s XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks ACCESS Newswire - Tue Apr 15, 3:30AM CDT

- Dermata previously announced XYNGARI(TM) produced highly statistically significant topline data for all primary endpoints at week 12 in Phase 3 trial -

DRMAW : 0.0186 (-25.60%)
DRMA : 2.14 (-1.83%)
Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules ACCESS Newswire - Thu Mar 27, 3:15PM CDT

SAN DIEGO, CA / ACCESS Newswire / March 27, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical...

DRMAW : 0.0186 (-25.60%)
DRMA : 2.14 (-1.83%)
Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results ACCESS Newswire - Mon Mar 17, 11:16AM CDT

- Dermata expects to announce topline results from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial by end of March 2025 -

DRMAW : 0.0186 (-25.60%)
DRMA : 2.14 (-1.83%)
Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis ACCESS Newswire - Tue Feb 25, 1:58AM CST

- This would be Dermata's second patent for DMT410, if issued, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis -

DRMAW : 0.0186 (-25.60%)
DRMA : 2.14 (-1.83%)
Dermata to Present on BioPub on January 31, 2025 ACCESS Newswire - Wed Jan 29, 10:05AM CST

- Dermata's Chief Executive Officer and Chief Development Officer will provide a corporate update and answer live questions from the biotech investment community -

DRMAW : 0.0186 (-25.60%)
DRMA : 2.14 (-1.83%)
Dermata Therapeutics Announces Closing of $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules ACCESS Newswire - Thu Jan 23, 3:15PM CST

SAN DIEGO, CA / ACCESS Newswire / January 23, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of...

DRMAW : 0.0186 (-25.60%)
DRMA : 2.14 (-1.83%)
Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules ACCESS Newswire - Wed Jan 22, 2:00AM CST

SAN DIEGO, CA / ACCESS Newswire / January 22, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of...

DRMAW : 0.0186 (-25.60%)
DRMA : 2.14 (-1.83%)
Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R) ACCESS Newswire - Tue Jan 21, 2:00AM CST

The Companies intend to first initiate a Phase 2a clinical trial evaluating Xyngari™ with Daxxify® to treat primary axillary hyperhidrosis -

DRMAW : 0.0186 (-25.60%)
DRMA : 2.14 (-1.83%)
RVNC : 3.65 (+0.27%)
Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM) ACCESS Newswire - Mon Dec 16, 2024

- Xyngari (formerly DMT310) is currently being studied in Phase 3 for the treatment of acne, with topline results from the first Phase 3 STAR-1 study expected in March 2025 -

DRMAW : 0.0186 (-25.60%)
DRMA : 2.14 (-1.83%)
Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne ACCESS Newswire - Tue Dec 10, 2024

- This is Dermata's first allowed U.S. patent application for DMT310, using its Spongilla technology to topically treat acne -

DRMAW : 0.0186 (-25.60%)
DRMA : 2.14 (-1.83%)

Barchart Exclusives

The 2 Riskiest Stocks Investors Are Betting On With Over 300% Upside Barchart - Sat Dec 20, 11:00AM CST
These biotech bets are only for investors who can stomach volatility. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot